| Bioactivity | BTO-1 is a Polo-like kinase (Plk) inhibitor. BTO-1 is primarily used for phosphorylation and dephosphorylation applications[1][2]. |
| Invitro | BTO-1 (50 μM; 4 hours; U20S cells) results in monopolar spindles in a comparable fraction of mitotic cells. BTO-1(20 μM; 1 hour; PTK cells) shows a dose-dependent reduction in phospho-Cdc25C. BTO-1(25 μM; 1 hour; PTK cells) shows about 20 % reduction in H3 phosphorylation compared to control cells. BTO-1 in HeLa cells results in a blockage of Rho and Rho-GEF recruitment, which is essential for the assembly of a functional contractile ring[1][2]. |
| Name | BTO-1 |
| CAS | 40647-02-7 |
| Formula | C9H4N4O4S |
| Molar Mass | 264.22 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Peters, U., et al. Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol 2, 618–626 (2006). [2]. Brennan IM, et al. Polo-like kinase controls vertebrate spindle elongation and cytokinesis. PLoS One. 2007;2(5):e409. Published 2007 May 2. |